| A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function (NCT04154774) | Janssen Research & Development, LLC | 2019-11-07 |
| A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (NCT04133636) | Janssen Research & Development, LLC | 2019-11-07 |
| A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants (NCT04147338) | Janssen Research & Development, LLC | 2019-10-30 |
| A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis (NCT04021862) | Janssen Research & Development, LLC | 2019-10-16 |
| A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (NCT04075396) | Janssen Research & Development, LLC | 2019-10-16 |
| A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease (NCT04068792) | Janssen Research & Development, LLC | 2019-10-10 |
| A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine (NCT04132557) | Janssen Research & Development, LLC | 2019-10-09 |
| A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets (NCT04121052) | Janssen Research & Development, LLC | 2019-10-08 |
| A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT04033445) | Janssen Research & Development, LLC | 2019-09-26 |
| A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease (NCT04102111) | Janssen Research & Development, LLC | 2019-09-23 |
| A Study of Paliperidone Palmitate 6-Month Formulation (NCT04072575) | Janssen Research & Development, LLC | 2019-09-19 |
| A Study of JNJ-61393215 in the Treatment of Depression (NCT04080752) | Janssen Research & Development, LLC | 2019-09-17 |
| A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants (NCT04087759) | Janssen Research & Development, LLC | 2019-09-16 |
| A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants (NCT04090086) | Janssen Research & Development, LLC | 2019-09-16 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa (NCT04019041) | Janssen Research & Development, LLC | 2019-09-16 |
| A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (NCT04077463) | Janssen Research & Development, LLC | 2019-09-04 |
| Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia (NCT04119050) | Janssen Research & Development, LLC | 2019-08-15 |
| A Study of Itraconazole in the Management of Superficial Fungal Infections in India (NCT03923010) | Janssen Research & Development, LLC | 2019-08-06 |
| A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants (NCT04033458) | Janssen Research & Development, LLC | 2019-07-29 |
| First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation (NCT04006301) | Janssen Research & Development, LLC | 2019-07-26 |
| A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed (NCT04012931) | Janssen Research & Development, LLC | 2019-07-18 |
| A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants (NCT03990519) | Janssen Research & Development, LLC | 2019-06-24 |
| A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery (NCT03891524) | Janssen Research & Development, LLC | 2019-06-17 |
| A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (NCT03767244) | Janssen Research & Development, LLC | 2019-06-11 |
| A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health (NCT03819049) | Janssen Research & Development, LLC | 2019-06-06 |
| Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab (NCT03871829) | Janssen Research & Development, LLC | 2019-05-31 |
| A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants (NCT03952507) | Janssen Research & Development, LLC | 2019-05-15 |
| A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors (NCT03926013) | Janssen Research & Development, LLC | 2019-05-01 |
| A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants (NCT03931447) | Janssen Research & Development, LLC | 2019-04-30 |
| A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (NCT03901963) | Janssen Research & Development, LLC | 2019-04-26 |
| A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer (NCT03871816) | Janssen Research & Development, LLC | 2019-04-22 |
| A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants (NCT03864601) | Janssen Research & Development, LLC | 2019-04-09 |
| A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants (NCT03953196) | Janssen Research & Development, LLC | 2019-04-08 |
| A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT03900598) | Janssen Research & Development, LLC | 2019-04-03 |
| A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT03915379) | Janssen Research & Development, LLC | 2019-03-28 |
| Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics Profiling (NCT03795402) | Janssen Research & Development, LLC | 2019-03-15 |
| A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants (NCT03800550) | Janssen Research & Development, LLC | 2019-02-13 |
| A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (NCT03748641) | Janssen Research & Development, LLC | 2019-01-25 |
| A Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (NCT03755128) | Janssen Research & Development, LLC | 2019-01-16 |
| A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants (NCT03802682) | Janssen Research & Development, LLC | 2019-01-11 |
| A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea (NCT03796026) | Janssen Research & Development, LLC | 2019-01-04 |
| A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants (NCT03808259) | Janssen Research & Development, LLC | 2018-12-20 |
| A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib (NCT03587363) | Janssen Research & Development, LLC | 2018-12-06 |
| A Study for Schizophrenia Relapse Prediction (NCT03629951) | Janssen Research & Development, LLC | 2018-11-29 |
| Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection (NCT03656510) | Janssen Research & Development, LLC | 2018-11-29 |
| A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (NCT03662542) | Janssen Research & Development, LLC | 2018-11-20 |
| A Study of Guselkumab in Participants With Familial Adenomatous Polyposis (NCT03649971) | Janssen Research & Development, LLC | 2018-11-19 |
| A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy (NCT03652064) | Janssen Research & Development, LLC | 2018-11-06 |
| Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus (NCT03502694) | Janssen Research & Development, LLC | 2018-11-05 |
| A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (NCT03596645) | Janssen Research & Development, LLC | 2018-10-29 |
| A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants (NCT03723746) | Janssen Research & Development, LLC | 2018-10-25 |
| A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities (NCT03713658) | Janssen Research & Development, LLC | 2018-10-18 |
| A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men (NCT03693391) | Janssen Research & Development, LLC | 2018-10-17 |
| A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants (NCT03696459) | Janssen Research & Development, LLC | 2018-10-02 |
| A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants (NCT03682380) | Janssen Research & Development, LLC | 2018-10-01 |
| A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy (NCT03384641) | Janssen Research & Development, LLC | 2018-09-26 |
| A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (NCT03563742) | Janssen Research & Development, LLC | 2018-09-24 |
| AAVCAGsCD59 for the Treatment of Wet AMD (NCT03585556) | Janssen Research & Development, LLC | 2018-09-13 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NCT03628924) | Janssen Research & Development, LLC | 2018-09-04 |
| A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer (NCT03523442) | Janssen Research & Development, LLC | 2018-08-31 |
| A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants (NCT03649997) | Janssen Research & Development, LLC | 2018-08-28 |
| A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants (NCT03593954) | Janssen Research & Development, LLC | 2018-07-31 |
| A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression (NCT03559192) | Janssen Research & Development, LLC | 2018-07-16 |
| A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin) (NCT03606057) | Janssen Research & Development, LLC | 2018-07-13 |
| A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS (NCT03573310) | Janssen Research & Development, LLC | 2018-07-13 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (NCT03451851) | Janssen Research & Development, LLC | 2018-07-11 |
| A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants (NCT03581916) | Janssen Research & Development, LLC | 2018-07-11 |
| A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose (NCT03586843) | Janssen Research & Development, LLC | 2018-06-29 |
| A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (NCT03548207) | Janssen Research & Development, LLC | 2018-06-29 |
| A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT03551782) | Janssen Research & Development, LLC | 2018-06-28 |
| A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus (NCT03586830) | Janssen Research & Development, LLC | 2018-06-26 |
| A Study of Bermekimab in Patients With Hidradenitis Suppurativa (NCT03512275) | Janssen Research & Development, LLC | 2018-06-20 |
| A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants (NCT03564379) | Janssen Research & Development, LLC | 2018-06-12 |
| A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function (NCT03546205) | Janssen Research & Development, LLC | 2018-06-06 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants (NCT03550950) | Janssen Research & Development, LLC | 2018-06-01 |
| Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat) (NCT03587376) | Janssen Research & Development, LLC | 2018-05-30 |
| A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (NCT03434041) | Janssen Research & Development, LLC | 2018-05-25 |
| A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis (NCT03496974) | Janssen Research & Development, LLC | 2018-05-21 |
| A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT03384654) | Janssen Research & Development, LLC | 2018-05-14 |
| A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older (NCT03500679) | Janssen Research & Development, LLC | 2018-05-09 |
| A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens (NCT03412565) | Janssen Research & Development, LLC | 2018-04-26 |
| A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT03462719) | Janssen Research & Development, LLC | 2018-04-17 |
| A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus (NCT03517722) | Janssen Research & Development, LLC | 2018-04-16 |
| A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (NCT03466411) | Janssen Research & Development, LLC | 2018-04-13 |
| A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN) (NCT03842189) | Janssen Research & Development, LLC | 2018-04-05 |
| A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants (NCT03486392) | Janssen Research & Development, LLC | 2018-03-26 |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (NCT03390504) | Janssen Research & Development, LLC | 2018-03-23 |
| A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants (NCT03468777) | Janssen Research & Development, LLC | 2018-03-06 |
| A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT03431350) | Janssen Research & Development, LLC | 2018-03-02 |
| A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease (NCT03492580) | Janssen Research & Development, LLC | 2018-02-22 |
| A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants (NCT03441529) | Janssen Research & Development, LLC | 2018-02-09 |
| A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions (NCT03438461) | Janssen Research & Development, LLC | 2018-02-09 |
| A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus (NCT03379675) | Janssen Research & Development, LLC | 2018-02-06 |
| A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis (NCT03358706) | Janssen Research & Development, LLC | 2018-02-02 |
| A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications (NCT03381196) | Janssen Research & Development, LLC | 2018-01-21 |
| A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection (NCT03332459) | Janssen Research & Development, LLC | 2018-01-05 |
| A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder (NCT03374475) | Janssen Research & Development, LLC | 2018-01-05 |
| A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection (NCT03376321) | Janssen Research & Development, LLC | 2018-01-03 |
| An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung (NCT03371381) | Janssen Research & Development, LLC | 2018-01-02 |
| A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants (NCT03405441) | Janssen Research & Development, LLC | 2018-01-02 |